Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Main Protease Inhibitors and Drug Surface Hotspot for the Treatment of COVID-19: Drug Repurposing and Molecular Docking Approach

17 April 2020, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The world is facing an unprecedented global pandemic caused by the novel SARS-CoV-2. In the absence
of a specific therapeutic agent to treat COVID-19 patients, the present study aimed to virtually screen out
the effective drug candidates from the approved main protease protein (MPP) inhibitors and their
derivatives for the treatment of SARS-CoV-2. Here, drug repurposing and molecular docking were
employed to screen approved MPP inhibitors and their derivatives. The approved MPP inhibitors against
HIV and HCV were prioritized, whilst hydroxychloroquine, favipiravir, remdesivir, and alpha-ketoamide
were studied as control. The target drug surface hotspot was also investigated through the molecular
docking technique. ADME analysis was conducted to understand the pharmacokinetics and drug-likeness
of the screened MPP inhibitors. The result of this study revealed that Paritaprevir (-10.9 kcal/mol), and its
analog (CID 131982844)(-16.3 kcal/mol) showed better binding affinity than the approved MPP inhibitor
compared in this study including favipiravir, remdesivir, and alpha-ketoamide. A comparative study among
the screened putative MPP inhibitors revealed that amino acids T25, T26, H41, M49, L141, N142, G143,
C145, H164, M165, E166, D187, R188, and Q189 are at critical positions for becoming the surface hotspot
in the MPP of SARS-CoV-2. The study also suggested that paritaprevir and its' analog (CID 131982844),
may be effective against SARS-CoV-2 as these molecules had the common drug-surface hotspots on the
main protease protein of SARS-CoV-2. Other pharmacokinetic parameters also indicate that paritaprevir
and its top analog (CID 131982844) will be either similar or better-repurposed drugs than already approved
MPP inhibitors.

Keywords

Main protease protein (MPP) inhibitors
SARS-CoV-2
COVID-19
Drug repurposing and Molecular docking

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Now Published

Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach [opens in a new tab]
Mahmudul Hasan, Md. Sorwer Alam Parvez, Kazi Faizul Azim, Md. Abdus Shukur Imran, Topu Raihan, Airin Gulshan, Samuel Muhit, Rubaiat Nazneen Akhand, Syed Sayeem Uddin Ahmed, Md Bashir Uddin journal article
Biomedicine & Pharmacotherapy , Volume 140
Print publication date: Aug, 2021

Version History

Apr 17, 2020 Version 1

Version Notes

This manuscript submitted to "Emerging Microbes and Infections" Journal

Metrics

3,601
1,129
1
Views
Downloads

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.12118857.v1
D O I: 10.26434/chemrxiv.12118857.v1 [opens in a new tab]

Author’s competing interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Share